Global

‡ In these countries please contact our distributor

Smith & Nephew opens state-of-the-art Research & Development Centre

12 May 2017

Alan Johnson MP opens R&D centre

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces that Rt Hon Alan Johnson has today opened its new £8 million state-of-the-art Research & Development (R&D) centre at its Hessle Road site in Hull.

The new centre will be one of the most well-equipped Medical Device R&D centres in Europe.  Its world-class facilities include Surface Analysis and Bio-Mechanics laboratories specialising in Toxicology, Chemistry and Microbiology among other specialist fields. The centre will contribute to driving research into pioneering methods of wound healing to better support healthcare professionals in their daily efforts to improve the lives of patients.

“Pioneering innovation is a strategic priority for Smith & Nephew and we are committed to delivering products that will make a meaningful difference to our customers and their patients,” commented Stewart McKinley, Vice President of Research & Innovation, Smith & Nephew. “The breadth and scale of scientific specialities that is based in this state-of-the-art R&D centre positions Smith & Nephew as world-class leaders in our industry.”

The R&D Centre is the latest investment in capital projects at the Hull site that have recently included bespoke manufacturing lines and flood defences. The Hessle Road site manufactures some of the most advanced wound care products on the market, including pioneering products such as PICO™, a unique single use negative pressure wound therapy system and ALLEVYN™ Life advanced foam dressings.

Founded in Hull over 160 years ago by Thomas James Smith, Smith & Nephew has grown from a Whitefriargate pharmacy to a global supplier of advanced medical devices with nearly 16,000 employees. During the First World War, it specialised in the supply of field dressings. Now, it manufactures pioneering products used by healthcare professionals in more than 100 countries.  Smith & Nephew is a Major Sponsor of Hull 2017, UK City of Culture.

Enquiries

Media

Tanya Childs, Corporate Brand Director
Smith & Nephew
+44 (0)1482 673857

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic ReconstructionAdvanced Wound ManagementSports Medicine and Trauma & Extremities, Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were almost $4.7 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.comfollow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

◊ Trademark of Smith & Nephew.  Certain marks registered US Patent and Trademark Office.

Smith & Nephew signs exclusive worldwide distribution agreement for the revolutionary MolecuLight i:XTM imaging device

Smith & Nephew invests in and signs agreement to distribute disruptive Leaf Healthcare pressure injury technology

Smith & Nephew Invests $55 Million in New Advanced Medical Technology Manufacturing Plant  

Smith & Nephew invests in new flood defences at its Hessle Road site in Hull